SCI

11 September 2024

New promises and challenges in the treatment of advanced non-small-cell lung cancer

（IF: Lancet, 98.4）

  • Meyer ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, Jänne PA, Peters S, Hirsch FR. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024 Aug 24;404(10454):803-822. 

  • Correspondence to: Fred R Hirsch, Center for Thoracic Oncology, Tisch Cancer Institute, Mount Sinai Health System, New York City, NY 10029, USA fred.hirsch@mssm.edu

Targeted therapies and immunotherapies have radically improved treatment for advanced non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver mutations continue to evolve over multiple generations to enhance effectiveness and tackle drug resistance. Immune checkpoint inhibitors remain integral for the treatment of NSCLCs that do not have specific actionable genetic mutations. Antibody–drug conjugates and bispecific antibodies are being integrated into treatment guidelines, and emerging therapies include T-cell engagers, cellular therapies, cancer vaccines, and external devices. Despite these advances, challenges remain in identifying predictive biomarkers to individually tailor treatments, abrogate resistance, reduce costs, and ensure optimal cancer treatment accessibility.

靶向治疗和免疫治疗从根本上改善了晚期非小细胞肺癌（NSCLC）的治疗方式。针对致癌驱动突变的小分子酪氨酸激酶抑制剂经过多代进化，以提高疗效并解决耐药问题。免疫检查点抑制剂对于没有特定可操作基因突变的NSCLC的治疗仍然至关重要。抗体-药物偶联物和双特异性抗体正在被整合到治疗指南中，新兴疗法包括T细胞受体、细胞疗法、癌症疫苗和外接设备。尽管已经取得了这些进展，但在识别预测性生物标志物以进行个体化定制治疗、克服耐药性、降低成本并确保最佳癌症治疗可及性方面仍存在挑战。


喜欢SCI天天读的理由

陪您一起学习SCI医学论文

每天5分钟，让自己的英语牛逼起来

特殊福利让您惊喜连连


复制链接或点击原文链接，即可下载SCI原文

W229N03

链接：https://pan.baidu.com/s/1siE7212ZStXmQxKPubfUjQ?pwd=2wj6

提取码：2wj6